A phase III trial of capivasertib and abiraterone versus placebo and abiraterone in patients with de novo metastatic hormone-sensitive prostate cancer characterized by PTEN deficiency (CAPItello-281).

Karim Fizazi,Daniel J. George,Maria De Santis,Noel W. Clarke,André P. Fay,Hirotsugu Uemura,Lynda Grinsted,Claire Rooney,Remy B Verheijen,Rana Anjum,Andrew Foxley,Thomas Morris

A phase III trial of capivasertib and abiraterone versus placebo and abiraterone in patients with de novo metastatic hormone-sensitive prostate cancer characterized by PTEN deficiency (CAPItello-281).

2021

Karim Fizazi
Daniel J. George
Maria De Santis
Noel W. Clarke
André P. Fay
Hirotsugu Uemura
Lynda Grinsted
Claire Rooney
Remy B Verheijen
Rana Anjum
Andrew Foxley
Thomas Morris

TPS178Background: In metastatic hormone-sensitive prostate cancer (mHSPC), abiraterone combined with androgen deprivation therapy (ADT) is highly effective in improving patient outcomes. However, a...

Keywords:

PTEN
Prostate cancer
Oncology
Abiraterone
Placebo
in patient
Androgen deprivation therapy
Internal medicine
Hormone sensitive prostate cancer
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations